Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on developing treatments for T cell-driven autoimmune diseases, has announced its participation in the upcoming TD Cowen 45th Annual Health Care Conference.
The company's president and CEO, Geoff McDonough, M.D., will deliver a presentation on Monday, March 3, 2025, at 9:10 a.m. ET in Boston. Investors and interested parties can access a live webcast of the presentation through the investor section of Generation Bio's website at investors.generationbio.com. The presentation recording will remain available for replay on the website for 30 days after the event.
Generation Bio (Nasdaq: GBIO), un'azienda biotecnologica focalizzata nello sviluppo di trattamenti per malattie autoimmuni guidate dalle cellule T, ha annunciato la sua partecipazione alla prossima 45ª Conferenza Annuale sulla Salute di TD Cowen.
Il presidente e CEO dell'azienda, Geoff McDonough, M.D., presenterà il suo intervento lunedì 3 marzo 2025, alle 9:10 a.m. ET a Boston. Gli investitori e le parti interessate possono accedere a una diretta web della presentazione attraverso la sezione investitori del sito web di Generation Bio all'indirizzo investors.generationbio.com. La registrazione della presentazione rimarrà disponibile per la visione on-demand sul sito per 30 giorni dopo l'evento.
Generation Bio (Nasdaq: GBIO), una empresa de biotecnología centrada en el desarrollo de tratamientos para enfermedades autoinmunes impulsadas por células T, ha anunciado su participación en la próxima 45ª Conferencia Anual de Salud de TD Cowen.
El presidente y CEO de la empresa, Geoff McDonough, M.D., hará una presentación el lunes 3 de marzo de 2025, a las 9:10 a.m. ET en Boston. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de inversores del sitio web de Generation Bio en investors.generationbio.com. La grabación de la presentación estará disponible para su reproducción en el sitio durante 30 días después del evento.
Generation Bio (Nasdaq: GBIO)는 T세포 주도 자가 면역 질환 치료 개발에 중점을 둔 생명공학 회사로, 다가오는 TD Cowen 제45회 연례 건강 관리 컨퍼런스에 참여한다고 발표했습니다.
회사의 사장 겸 CEO인 Geoff McDonough, M.D.는 2025년 3월 3일 월요일 오전 9:10 ET에 보스턴에서 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Generation Bio 웹사이트의 투자자 섹션을 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다. 발표 녹화는 이벤트 후 30일 동안 웹사이트에서 다시 볼 수 있습니다.
Generation Bio (Nasdaq: GBIO), une entreprise de biotechnologie axée sur le développement de traitements pour les maladies auto-immunes à médiation T, a annoncé sa participation à la prochaine 45ème Conférence Annuelle sur la Santé de TD Cowen.
Le président et CEO de l'entreprise, Geoff McDonough, M.D., présentera le lundi 3 mars 2025, à 9h10 ET à Boston. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section investisseurs du site web de Generation Bio à l'adresse investors.generationbio.com. L'enregistrement de la présentation restera disponible en replay sur le site pendant 30 jours après l'événement.
Generation Bio (Nasdaq: GBIO), ein biotechnologisches Unternehmen, das sich auf die Entwicklung von Behandlungen für T-Zell-gesteuerte Autoimmunerkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt.
Der Präsident und CEO des Unternehmens, Geoff McDonough, M.D., wird am Montag, den 3. März 2025, um 9:10 Uhr ET in Boston eine Präsentation halten. Investoren und Interessierte können über den Investorenbereich der Website von Generation Bio unter investors.generationbio.com auf einen Live-Stream der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird 30 Tage nach der Veranstaltung auf der Website verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is a biotechnology company changing what's possible for people living with T cell-driven autoimmune diseases. The company is developing a new modality of therapeutics leveraging its T cell-selective cell-targeted lipid nanoparticle (ctLNP) to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction. By selectively modulating T cells that drive disease pathology, ctLNP-siRNA therapeutics could potently block target function with sequence-level specificity while sparing the broader immune system. This potent new modality is designed to reach targets that are poorly drugged by other approaches, opening a broad indication space of T cell-driven autoimmune diseases.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
When is Generation Bio (GBIO) presenting at the TD Cowen Health Care Conference 2025?
How can investors watch Generation Bio's (GBIO) TD Cowen conference presentation?
What is the focus area of Generation Bio's (GBIO) research and development?
Who will represent Generation Bio (GBIO) at the TD Cowen Healthcare Conference 2025?
